IgG3, Hinge Region

Référence I1904-86G-500ug

Conditionnement : 500ug

Marque : US Biological



I1904-86G IgG3, Hinge Region

Clone Type
Monoclonal
Host
mouse
Source
human
Swiss Prot
P01860
Isotype
IgG1,k
Grade
Purified
Applications
E FC IHC
Crossreactivity
Hu
Gene #
IGHG3
Shipping Temp
Blue Ice
Storage Temp
-20°C

Applications:
Suitable for use in ELISA, Flow Cytometry and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
ELISA: ≤1ug/ml
Immunohistochemistry: paraffin sections
Optimal dilutions to be determined by the researcher.

Recommended Secondary Antibodies:
I1904-65W: IgG, F(ab’)2 (HRP) Pab RbxMo
I1904-66C: IgG, F(ab’)2, X-Adsorbed (HRP) Pab RbxMo
I1903-13A: IgG, F(ab’)2, X-Adsorbed (PE) Pab GtxMo

Recommended Negative Control:
I1904-78R: IgG1 Murine Negative Control

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Product Type: Mab|Isotype: IgG1,k|Clone No: 3H2421 (HP6050)|Host: mouse|Source: human|Concentration: ~0.5mg/ml|Form: Supplied as a liquid in Borate buffered saline, pH 8.2. No|preservatives or amine-containing buffer salts added.|Purity: Purified|Immunogen: Human IgG3 myeloma protein|Specificity: Recognizes human IgG3, binding to an epitope at the hinge region. ||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Human IgG3 myeloma protein
Form
Supplied as a liquid in Borate buffered saline, pH 8.2. No|preservatives or amine-containing buffer salts added.
Purity
Purified
Specificity
Recognizes human IgG3, binding to an epitope at the hinge region.
References
1. Jefferis, R. et al. (1985). Immunol. Lett. 10: 223-252. 2. Jefferis R et al (1980). Immunol 81: 357-367. 3. Mutapi, F. et al. (2002) The effect of treatment on the age-antibody relationship in children infected with Schistosoma mansoni and Schistosoma haematobium. Mem Inst Oswaldo Cruz. 97 Suppl 1: 173-80.